Pazopanib HCl (GW786034 HCl)

Catalog No.S1035

Pazopanib HCl (GW786034 HCl) Chemical Structure

Molecular Weight(MW): 473.98

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. (B): VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined at indicated times in the presence or absence of Pazopanib.

    J Virol, 2011, 85(5): 2296-303. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

    MRC5 non-transformed human lung fibroblasts were infected with influenza viruses (100 multiplicity of infection). Two hours after infection the cells were treated with vehicle control; sorafenib tosylate (2mM); pazopanib (2mM); OSU-03012 (2mM); and AR-13 (2mM). Twenty-four hours after infection the cells are treated with live/dead agent where green cells are viable and cells staining yellow or red are considered dead. Cells are examined at 10 magnification in a Hermes wide-field microscope (n¼3 SEM) P<0.05 less than vehicle control level of virus-mediated cell killing.

    J Cell Physiol, 2016, 231(10):2286-302.. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

  • Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Features A multi-kinase inhibitor.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
FGFR [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HUVEC NGnWfVFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnnkbY5pcWKrdIOgeIhmKF[HR1[tbY5lfWOnZDDwdo9tcW[ncnH0bY9vKG:oIFjVWmVEew>? M3H4R|E5PjJyM{iy
HUVEC MVvLbY5ie2ViYYPzZZk> NGHOcllqdmirYnn0d{BXTUeILXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIG\FS2ZTNTJiaX6gTHVXTUNiY3XscJMhf2m2aDDhckBKSzVyIH;mJQKJxDhibl2= M1X4XVE5PjJyM{iy
MM NYTYNVJbU2mwYYPlJIF{e2G7 M1rmWYlvcGmkaYTzJHZGT0ZvaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiZnz0NS=> MmiyNVcyPjR|M{K=
MM.1S NVLFSYV5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYGxNEDPxGdxbVy= NIn0bJVqdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= MXuxO|E3PDN|Mh?=
MM.1R M4fod2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MoXKNVAh|rypL33M MXXpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? MV6xO|E3PDN|Mh?=
RPMI NEfvUYlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MV6xNEDPxGdxbVy= MUjpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? MVWxO|E3PDN|Mh?=
Dox40 MoriS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NEnYc|MyOCEQvHevcWw> M33TNolvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq M2fwb|E4OTZ2M{Oy
INA-6 NVnNWXZVT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3HUXlExKM7:Zz;tUC=> M4nlZYlvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq M3vsU|E4OTZ2M{Oy
OPM2 MlXHS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXL5XYRGOTBizsznM41N NHvqfnRqdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= MorqNVcyPjR|M{K=
U266 MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M322d|ExKM7:Zz;tUC=> MYDpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? MkXiNVcyPjR|M{K=
MM.1S M4jKVIN6fG:2b4jpZ4l1gSCjc4PhfS=> NVzSNZBlOjBizsznM41N M{XUcolvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NG\oVpUyPzF4NEOzNi=>
MM.1R MnLPZ5l1d3SxeHnjbZR6KGG|c3H5 NF7Nb|EzOCEQvHevcWw> M4nKTIlvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NX;6SpgzOTdzNkSzN|I>
RPMI NYDDW4hl[3m2b4TvfIlkcXS7IHHzd4F6 NXHhOZBrOjBizsznM41N M{PXcolvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NVPpfZVwOTdzNkSzN|I>
Dox40 MkTuZ5l1d3SxeHnjbZR6KGG|c3H5 NVn2RnAzOjBizsznM41N MVfpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu M{TqTlE4OTZ2M{Oy
INA-6 MoPtZ5l1d3SxeHnjbZR6KGG|c3H5 M4X0WlIxKM7:Zz;tUC=> M3vTR4lvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= MVWxO|E3PDN|Mh?=
OPM2 MVfjfZRwfG:6aXPpeJkh[XO|YYm= MYiyNEDPxGdxbVy= M3TBVIlvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= MlHaNVcyPjR|M{K=
U266 M3H6doN6fG:2b4jpZ4l1gSCjc4PhfS=> NF\rZXYzOCEQvHevcWw> MoO4bY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= NYT3eGdGOTdzNkSzN|I>
MM.1S Mk[zSpVv[3Srb36gZZN{[Xl? NWXn[ItDe3WycILld5NmeyCYRVfGMWlv\HWlZXSgSY5ld3SqZXzpZYwhS2WubDDQdo9tcW[ncnH0bY9vKGGwZDDNbYdz[XSrb36u MnL1NVcyPjR|M{K=
MM.1R MUPGeY5kfGmxbjDhd5NigQ>? NGLZdGd{fXCycnXzd4V{KF[HR1[tTY5lfWOnZDDFcoRwfGinbHnhcEBE\WyuIGDyc4xq\mW{YYTpc44h[W6mIF3p[5JifGmxbj6= NWHQcmJFOTdzNkSzN|I>
Dox40 Mn7ESpVv[3Srb36gZZN{[Xl? NYPQT3d3e3WycILld5NmeyCYRVfGMWlv\HWlZXSgSY5ld3SqZXzpZYwhS2WubDDQdo9tcW[ncnH0bY9vKGGwZDDNbYdz[XSrb36u M1PxXFE4OTZ2M{Oy
OPM2 MXPGeY5kfGmxbjDhd5NigQ>? MXjzeZBxemW|c3XzJHZGT0ZvSX7keYNm\CCHbnTveIhmdGmjbDDD[YxtKFC{b3zp[oVz[XSrb36gZY5lKE2rZ4LheIlwdi5? MWWxO|E3PDN|Mh?=
HBMEC M{[4Nmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NG[4V4l,OTBizszN NI\FbXpFVVOR MonwTWM2OD1zIN88US=> MlK5NlExQDF4NU[=
HBMEC MlTuSpVv[3Srb36gZZN{[Xl? MWD+NUDPxE1? MWHEUXNQ NXfnSJps[WK{b3fheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gWmVITlJ{IIfpeIgh\Gm|coXweIlwdiCxZjDkc5dve3S{ZXHtJHBNS87|MR?= NWPUPVU3OjFyOEG2OVY>
HBMEC NELUbXFHfW6ldHnvckBie3OjeR?= M3nJNJ4yKM7:TR?= NYfQZ5pMTE2VTx?= M4DYXYRqe3K3cITzJJRp\SCUYYOtVoFnNUWUSzDwZZRpf2G7IITodo92\2hiZHXjdoVie2WmIIDoc5NxcG:{eXzheIVlKE2HS{GvNkBidmRiRWLLNU8z MX6yNVA5OTZ3Nh?=
HBMEC MULGeY5kfGmxbjDhd5NigQ>? MnXkglIxKM7:TR?= NFTY[lBFVVOR M3nte4Rqe3K3cITzJFUxLSCxZjD0eYJmKG[xcn3heIlwdiCjdDCxJO69VQ>? NV;nbI4yOjFyOEG2OVY>
MDA-MB-231 NEXEPG5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2HqfJ4yOCEQvF2= MYXEUXNQ MnzNTWM2OD13IN88US=> MYKyNVA5OTZ3Nh?=
MDA-MB-231 Moq3SpVv[3Srb36gZZN{[Xl? M1TGXVAvPSEQvF2= MU\EUXNQ Mo\hbY5pcWKrdIOgeIhmKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfS=> NEXiRlYzOTB6MU[1Oi=>
MDA-MB-231 Mmr2SpVv[3Srb36gZZN{[Xl? NFrx[ZQ2KM7:TR?= M1HjcmROW09? MmTzbY5lfWOnczDhJINmdGxvY4njcIUh[XK{ZYP0 NFnRXYszOTB6MU[1Oi=>
J82 NIj3cXFkgXSxdH;4bYNqfHliYYPzZZk> M{ixNp4yOCEQvF2= NIHqN29FVVOR MlPRTWM2OD1{ND61O{DPxE1? NXTCZmtKOjF3Mkm5NFA>
T24 MYTjfZRwfG:6aXPpeJkh[XO|YYm= NYKxOYV2hjFyIN88US=> MVHEUXNQ NUjVXJRWUUN3ME21Nk41PSEQvF2= NUf6eZRzOjF3Mkm5NFA>
HT1376 M1zob4N6fG:2b4jpZ4l1gSCjc4PhfS=> M13ycJ4yOCEQvF2= NUnYZVdNTE2VTx?= M{DLWmlEPTB;MkiuNlEh|ryP M2TSSlIyPTJ7OUCw
RT4 MlXVZ5l1d3SxeHnjbZR6KGG|c3H5 MVT+NVAh|ryP MmPrSG1UVw>? M1iwZWlEPTB;NT6xOEDPxE1? MkTzNlE2Ojl7MEC=
CRL1749 NIPLU3RkgXSxdH;4bYNqfHliYYPzZZk> NUfrU4FRhjFyIN88US=> MX7EUXNQ MVLJR|UxRTJ{Lk[5JO69VQ>? M2exZ|IyPTJ7OUCw
HTB9 NInIOYlkgXSxdH;4bYNqfHliYYPzZZk> NYPiXVE3hjFyIN88US=> M2[wcmROW09? MmLLTWM2OD1zMT64OEDPxE1? NWjMZVJvOjF3Mkm5NFA>
Sup NXTLcpU{[3m2b4TvfIlkcXS7IHHzd4F6 NYH0SVR4hjFyIN88US=> MXzEUXNQ MU\JR|UxRTV|LkOyJO69VQ>? NIjpblMzOTV{OUmwNC=>
HTB3 NY\1eoNS[3m2b4TvfIlkcXS7IHHzd4F6 M1ntc54yOCEQvF2= NHK2bmNFVVOR MXzJR|UxRTF2LkG2JO69VQ>? MV2yNVUzQTlyMB?=
CEC NVjBOGRKTnWwY4Tpc44h[XO|YYm= NF7uT45,OTBizsznM41N NFTrU3BFVVOR MYTkc5dvNXKnZ4XsZZRmeyCYRVfGJIxmfmWucx?= MWeyNVYzODh{Mh?=
RPE NILwUnZHfW6ldHnvckBie3OjeR?= M{j3R54yOCEQvHevcWw> Mo\NSG1UVw>? M3\r[YRwf25vcnXneYxifGW|IG\FS2YhdGW4ZXzz MXSyNVYzODh{Mh?=
CEC NUiwPJFKTnWwY4Tpc44h[XO|YYm= M4TRdJ42KM7:Zz;tUC=> NF7oWI5FVVOR NWja[WFJ[myxY3vzJIVv\G:2aHXsbYFtKGOnbHygcYloemG2aX;u M2PkdFIyPjJyOEKy
5637 MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MlPoSG1UVw>? MUPJR|UxRTF3LkFihKnPxE1? Mk\UNlM5QDd4MEW=
J82 M4[wSWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2fQN2ROW09? NVH5fpVEUUN3ME2xPE416oDLzszN MVKyN|g5PzZyNR?=
5637 MXLBeZRweGijZ4mgZZN{[Xl? NFXoRpEzOCEQvF2= NVSxW2VTTE2VTx?= MkP2eJJq\2encoOgeIhmKGG3dH;wbIFocWNicILvZ4V{ew>? NU\l[mY2OjN6OEe2NFU>
J82 NGrQUGFCfXSxcHjh[5kh[XO|YYm= MWKyNEDPxE1? M3voZ2ROW09? MWX0dolo\2W{czD0bIUh[XW2b4DoZYdq[yCycn;j[ZN{ M1XTZ|I{QDh5NkC1
5637 MVLGeY5kfGmxbjDhd5NigQ>? NIfFW3QzOCEQvF2= MXLEUXNQ MmTDbY5lfWOnczDsfZNwe2:vYXyt[IVx\W6mZX70JI5m[3Kxc3nz NYnDd5gzOjN6OEe2NFU>
J82 NHvycGlHfW6ldHnvckBie3OjeR?= M{XD[lIxKM7:TR?= NYHPbW1jTE2VTx?= M17Dd4lv\HWlZYOgcJl{d3OxbXHsMYRmeGWwZHXueEBv\WO{b4Ppdy=> M4S0dlI{QDh5NkC1
5637 M13zTGZ2dmO2aX;uJIF{e2G7 NVv0TFMxOjBizszN MX7EUXNQ NHfvXXFqdmS3Y3XzJIx6e2:|b33lJIFtfGW{YYTpc44h[W6mIHnubIljcXS|IFPCJIFkfGm4aYT5 MYOyN|g5PzZyNR?=
J82 MWDGeY5kfGmxbjDhd5NigQ>? M4j4clIxKM7:TR?= M{LQRmROW09? MXjpcoR2[2W|IHz5d49{d22nIHHseIVz[XSrb36gZY5lKGmwaHnibZR{KEOEIHHjeIl3cXS7 M3zQO|I{QDh5NkC1
KATO-II MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEj1PFM2KM7:TR?= Ml7qSG1UVw>? MVTicI9kc3NicILvcIln\XKjdHnvci=> M33BXVI2OjR7NUW3
OCUM-2M MmjiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHzqPGY2KM7:TR?= M{HVTGROW09? NFvnSm5jdG:la4OgdJJwdGmoZYLheIlwdg>? MX6yOVI1QTV3Nx?=
SNU-16 MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MWG1JO69VQ>? MXzEUXNQ M4O1bIJtd2OtczDwdo9tcW[ncnH0bY9v MYGyOVI1QTV3Nx?=
HSC-39 MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXPmfnhlPSEQvF2= MXnEUXNQ MV3icI9kc3NicILvcIln\XKjdHnvci=> Mnj3NlUzPDl3NUe=
KATO-II NITyVVJkgXSxdH;4bYNqfHliYYPzZZk> NXPlXpd4hjFyIN88US=> MWTEUXNQ NX61b|czUUN3ME2wMlEhfG9iMj6wJO69dW:uL1y= M1;IfFI2OjR7NUW3
OCUM-2M MkPUZ5l1d3SxeHnjbZR6KGG|c3H5 M1mzUJ4yOCEQvF2= NYThbGtjTE2VTx?= NGHKToRKSzVyPUCuNUB1dyB{LkCg{txud2xxTB?= MkjRNlUzPDl3NUe=
SNU-16 MkmyZ5l1d3SxeHnjbZR6KGG|c3H5 MnXJglExKM7:TR?= NHPO[|RFVVOR MnTETWM2OD1yLkGgeI8hOi5yIN88cY9tN0x? NXnO[ZR6OjV{NEm1OVc>
HSC-39 Mm\CZ5l1d3SxeHnjbZR6KGG|c3H5 MkfXglExKM7:TR?= NE[wc3BFVVOR M1npS2lEPTB;MD6xJJRwKDJwMDFOwI1wdC:O M1vWNFI2OjR7NUW3
NIH 3T3 MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEf6Vo9,OTBizszN MlfYSG1UVw>? NYPpUpBJcW6qaXLpeJMh[2WubDDndo94fGhiYX7kJINwdG:weTDmc5Ju[XSrb36= NFLkXZkzPTJ2OUW1Oy=>
KATO-III MoXsSpVv[3Srb36gZZN{[Xl? NESxS40yKM7:TR?= M1nTW2ROW09? MmrHbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dB?= NEHV[lIzPTJ2OUW1Oy=>
OCUM-2M MknnSpVv[3Srb36gZZN{[Xl? NV[0dYZPOSEQvF2= NWHjN4FCTE2VTx?= M1XrOolv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= NFzmZmQzPTJ2OUW1Oy=>
KATO-III NUS5TJNFSXCxcITvd4l{KGG|c3H5 MoPDNUDPxE1? M1;SeGROW09? M33qc4lv\HWlZYOgZZBweHSxc3nz NUjw[YJKOjV{NEm1OVc>
OCUM-2M NXK3WHZISXCxcITvd4l{KGG|c3H5 NEWwR5kyKM7:TR?= MULEUXNQ MlXRbY5lfWOnczDhdI9xfG:|aYO= MmXvNlUzPDl3NUe=
KATO-III NWfyO|BETnWwY4Tpc44h[XO|YYm= M1T5dFEh|ryP NGjCfItFVVOR NHX3eHpqdmirYnn0d{BHT0[UMjDwbI9{eGixconsZZRqd25iYX7kJIRwf26|dILlZY0he2mpbnHsbY5oKG2xbHXjeYxmew>? NVvUU5FlOjV{NEm1OVc>

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase enzyme assays:

VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.
Cell Research:

[1]

+ Expand
  • Cell lines: HUVEC cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1 hour
  • Method:

    Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (35.86 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 473.98
Formula

C21H23N7O2S.HCl

CAS No. 635702-64-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03735758 Recruiting Soft Tissue Sarcoma Adult GWT-TUD GmbH November 2 2018 Phase 4
NCT03660930 Not yet recruiting Soft Tissue Sarcoma University of Washington October 25 2018 Phase 1|Phase 2
NCT03628131 Not yet recruiting Relapsed Pediatric Solid Tumor|Refractory Pediatric Solid Tumor Samsung Medical Center|Ministry of Health Republic of Korea October 2018 Phase 1|Phase 2
NCT03592472 Recruiting Renal Cell Carcinoma Xynomic Pharmaceuticals Inc. July 17 2018 Phase 3
NCT03275558 Withdrawn Recurrent Glioblastoma|Gliosarcoma|Anaplastic Gliomas Center Trials & Treatment July 17 2018 Phase 1
NCT03334409 Recruiting Clear Cell Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v7 Academic and Community Cancer Research United|National Cancer Institute (NCI) February 16 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products4

Tags: buy Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) supplier | purchase Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) cost | Pazopanib HCl (GW786034 HCl) manufacturer | order Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID